MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Operating income 2016–2025
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) annual operating income history from SEC filings — each fiscal year as reported.
-$7.0MFY2025 · since FY2016: -$8.3M → -$7.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.0M | +71.7% |
| FY2024 | -$24.6M | -3.5% |
| FY2023 | -$23.8M | +3.4% |
| FY2022 | -$24.6M | +0.6% |
| FY2021 | -$24.7M | -2.2% |
| FY2020 | -$24.2M | -27.9% |
| FY2019 | -$18.9M | -29.2% |
| FY2018 | -$14.6M | +11.2% |
| FY2017 | -$16.5M | -99.9% |
| FY2016 | -$8.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MTNB financial trends
MTNB RevenueMTNB Net incomeMTNB Net marginMTNB Gross profitMTNB Gross marginMTNB Operating marginMTNB Operating cash flowMTNB Free cash flowMTNB Capital expendituresMTNB Return on equityMTNB Stock buybacksMTNB Dividends paidMTNB Total assetsMTNB Total liabilitiesMTNB Shareholders’ equityMTNB overview →